Losartan, marketed under the brand name Cozaar among others, is a cornerstone medication in the management of cardiovascular and renal conditions. As the first orally active, non-peptide angiotensin II receptor blocker (ARB) to be approved for clinical use, it represents a significant advancement in the renin-angiotensin-aldosterone system (RAAS) inhibition therapy. This report details its mechanism of action, therapeutic uses, pharmacokinetics, side effects, and important considerations.

1. Pharmacology and Mechanism of Action
Losartan's primary mechanism involves selective and competitive antagonism of the angiotensin II type 1 (AT1) receptor. Angiotensin II is a potent vasoconstrictor peptide that also stimulates aldosterone secretion, leading to sodium and water retention, and promotes cellular growth and proliferation. By blocking the AT1 receptor, losartan inhibits these effects. Unlike angiotensin-converting enzyme (ACE) inhibitors, which prevent the formation of angiotensin II, losartan directly blocks its action at the receptor level. This direct blockade avoids the accumulation of bradykinin associated with ACE inhibitors, which is thought to be responsible for the dry cough common with that drug class. Notably, the blockade of the AT1 receptor leads to a compensatory increase in angiotensin II levels, which then stimulates the unblocked angiotensin II type 2 (AT2) receptors. AT2 receptor stimulation may confer additional beneficial effects, such as vasodilation and anti-proliferative actions.

2. Pharmacokinetics
Losartan is well absorbed orally but undergoes substantial first-pass metabolism, resulting in an oral bioavailability of approximately 33%. It is metabolized in the liver by cytochrome P450 enzymes (primarily CYP2C9 and CYP3A4) to an active carboxylic acid metabolite (E-3174), which is many times more potent than the parent drug and has a longer half-life (6-9 hours versus 2 hours for losartan). Both the parent drug and the active metabolite are highly bound to plasma proteins (>98%). Excretion occurs via both urine and bile. The pharmacokinetics can be affected by hepatic impairment, necessitating dose adjustment, but are not significantly altered in renal impairment. Food does not clinically affect its absorption.

3. Clinical Applications
Losartan is indicated for several conditions, primarily through its antihypertensive and organ-protective effects.
Hypertension: It is a first-line agent for the management of essential hypertension, effectively lowering blood pressure by reducing peripheral vascular resistance. It can be used as monotherapy or in combination with other antihypertensives like diuretics (e.g., losartan/hydrochlorothiazide).
Diabetic Nephropathy: For patients with type 2 diabetes and hypertension, losartan is proven to slow the progression of renal disease, as evidenced by reducing proteinuria and delaying the onset of end-stage renal disease. This nephroprotective effect is independent of its blood pressure-lowering action.
Heart Failure: It is used in the treatment of heart failure with reduced ejection fraction (HFrEF) when patients are intolerant to ACE inhibitors, as it reduces afterload and prevents adverse cardiac remodeling.
Stroke Risk Reduction in LVH: Losartan is indicated for the reduction of stroke risk in patients with hypertension and left ventricular hypertrophy (LVH), as demonstrated in the landmark LIFE trial, though it does not necessarily reduce LVH more than other therapies.

4. Dosage and Administration
The typical starting dose for hypertension is 50 mg once daily, which can be titrated to 100 mg once daily. For volume-depleted patients (e.g., those on high-dose diuretics), Levitra 10mg (https://rache.es/producto/levitra) a starting dose of 25 mg is recommended. In diabetic nephropathy, the standard dose is 50-100 mg daily. It can be taken with or without food. The full antihypertensive effect is usually attained within 3-6 weeks.

5. Adverse Effects and Safety Profile
Losartan is generally well-tolerated. Common side effects, which are often mild and transient, include dizziness, upper respiratory tract infection, and fatigue. Unlike ACE inhibitors, the incidence of dry cough is very low (approximately equivalent to placebo). Serious but rare adverse effects include:
Hypotension: Especially in volume-depleted patients.
Hyperkalemia: Due to reduced aldosterone secretion, particularly in patients with renal impairment, diabetes, or those concurrently using potassium-sparing diuretics, potassium supplements, or NSAIDs.
Renal Impairment: In susceptible individuals (e.g., bilateral renal artery stenosis), it can cause acute renal failure due to efferent arteriolar dilation and a drop in glomerular filtration pressure.
Angioedema: A rare but serious class-effect of ARBs, involving swelling of the face, lips, tongue, or larynx.
Teratogenicity: Like all drugs affecting the RAAS, losartan is contraindicated in pregnancy (especially second and third trimesters) due to risks of fetal injury and death.

6. Drug Interactions
Significant interactions include:
Potassium-raising agents: Concomitant use with potassium-sparing diuretics (spironolactone), potassium supplements, or salt substitutes increases hyperkalemia risk.
NSAIDs: Drugs like ibuprofen or naproxen can attenuate the antihypertensive effect and increase the risk of renal dysfunction.
Lithium: Losartan may decrease lithium excretion, increasing the risk of lithium toxicity.

• Other antihypertensives: Additive blood pressure-lowering effects with other agents.
  
  

Losartan is contraindicated in patients with known hypersensitivity to any component, in pregnancy, and in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy. Caution is required in patients with hepatic impairment (consider lower starting dose), renal artery stenosis, pre-existing renal insufficiency, and heart failure with concomitant diuretic therapy. Regular monitoring of serum potassium, creatinine, and blood pressure is recommended, especially during initiation and titration.

8. Conclusion
Losartan remains a fundamental therapeutic agent in modern medicine. Its specific mechanism as an AT1 receptor blocker provides effective blood pressure control and confers proven renal and cardiovascular protective benefits, particularly in patients with diabetes and hypertension. Its favorable tolerability profile, especially the low incidence of cough, makes it a valuable alternative to ACE inhibitors. However, prudent clinical use requires awareness of its potential for hyperkalemia, renal effects, and absolute contraindication in pregnancy. As part of a comprehensive management strategy, losartan significantly contributes to improving long-term outcomes for millions of patients worldwide.